Evelyn Warner, Author at Labiotech.eu

About

Ex-Editor. Recovering organic chemist. Chagrined member of the Brooklyn-Berlin exchange program. Proud parent of a majestic domestic long hair.

Articles by Evelyn Warner

News and Trends 5 Jul 2017

Cutting Through the BS in Biopharma: How To Spot Hype

Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in June, I headed to Copenhagen last week for the European Conference for Science Journalists to cajole a panel into discussing how some of these stories feature […]

July 5, 2017 - 4 minutesmins - By Evelyn Warner

Interview 3 Jul 2017

Video: Is mRNA a True Game-Changer? Fireside Chat with Sean Marett, COO of BioNTech

Sean Marett took a red-eye from New York to speak at Refresh last month: here are his thoughts on how mRNA therapeutics are taking biotech by storm! mRNA has become one of the next big things in biotech, and Germany-based BioNTech is at the forefront of the wave, developing personalized treatments for cancer. “We try to provide individualized […]

July 3, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 3 Jul 2017

Scottish AI Biotech Recruits Another Pharma Partner in €37M Deal

After Sanofi recruited Exscientia in a €250M deal last May, GSK has taken an interest in the startup and invested in a collaboration of its own. Artificial intelligence has been carving out a niche for itself in biotech, and Exscientia is fast establishing itself as a key player in the field. In May, the company signed a […]

July 3, 2017 - 1 minutemin - By Evelyn Warner

Interview 3 Jul 2017

These Norwegian Biotech Execs are Bringing Back Cancer Vaccines & Oncolytic Viruses

We talked to CEO Øystein Soug and CMO Magnus Jäderberg of Targovax about why the company’s technologies may succeed where others have failed. In 2010, Targovax rose from the ashes of Norsk Hydro Pharma, the discontinued therapeutic development arm of the conglomerate. The Oslo-based biotech is taking a stand against tough-to-treat cancers like that of […]

July 3, 2017 - 8 minutesmins - By Evelyn Warner

News and Trends 26 Jun 2017

Videos: Who won the Refresh Early-Stage Startup Battle? The Bonsai goes to…

As you might have read in our recap, we had not one but two startup battles for the last edition of Refresh. Watch the companies’ pitches below! Up first was Cambridge Cancer Genomics, which uses AI to design personalised DNA-based tests to help clinicians to better track their patients’ responses to cancer drugs in order to make […]

June 26, 2017 - 2 minutesmins - By Evelyn Warner

Interview 26 Jun 2017

Meet the Gynecologist at the Helm of Geneva’s Star Biotech

Ernest Loumaye began as a doctor at a university hospital and is now CEO of ObsEva. We chatted about how biotech supports women’s health. ObsEva, one of the top biotechs in Geneva that made this year’s first IPO for a huge €90M, is not Ernest Loumaye’s first company. Though he began as the gynecologist in charge of the reproductive […]

June 26, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 22 Jun 2017

French Nonprofit Partners with Big American Name to Advance a Gene Therapy for Muscular Dystrophy

Noble Généthon has teamed up with ignominious Sarepta to develop a gene therapy for the Duchenne variety of the muscle wasting disease. Dedicated to rare diseases since 1990 and more recently to gene therapy, Généthon is one of very few not-for-profit companies in European biotech. Though it has not yet brought a drug to market, it is […]

June 22, 2017 - 3 minutesmins - By Evelyn Warner

Interview 22 Jun 2017

Live Labiotech Hangout: Join our second webcast on synthetic biology, entrepreneurship and academia!

Join us for our second live Hangout with serial synbio entrepreneur but determined academic, Morten Sommer, which will be streaming live next week Thursday June 29th at 5:00pm CET! Click to Join the Hangout We can’t wait for an event to produce videos for our readers, and we realized we don’t have to! Next week is the second […]

June 22, 2017 - 1 minutemin - By Evelyn Warner

More News! 20 Jun 2017

Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […]

June 20, 2017 - 1 minutemin - By Evelyn Warner

Interview 12 Jun 2017

This Italian Academic-turned-CEO also Launched 7 Cancer Drugs at GSK

Paolo Paoletti might have been forced to reconsider his career as a professor in medicine, but academia’s loss was biopharma’s gain! Before becoming CEO of one of London’s most exciting biotechs, GammaDelta Therapeutics, Paolo Paoletti had a long run through the corporate ranks of pharma. He was coaxed out of academic medicine to join Eli […]

June 12, 2017 - 9 minutesmins - By Evelyn Warner

Interview 8 Jun 2017

Cambridge Antibody Technology: The History of the UK’s Best Biotech

CAT was the first of Greg Winter’s three antibody-related companies and one of the UK’s biggest success stories in biotech. How did he pull it off? Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation […]

June 8, 2017 - 7 minutesmins - By Evelyn Warner

Interview 5 Jun 2017

What Lies Ahead in Biotech for the UK’s Top Academic Entrepreneur?

Despite remaining firmly in academia, Greg Winter is a biotech legend. What’s ahead for the serial entrepreneur, and where does he see biotech going? Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation of his first […]

June 5, 2017 - 7 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us